XENE
Xenon Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · CA
$35.08
+4.75%Oct 1, 2026, 13:23 UTC
Xenon Pharmaceuticals director, president and CEO Ian Mortimer bought 30,000 company shares for $1,121,400 on September 30, 2026, per a Form 4 filed with the SEC.
Source:Sep 22, 2026, 22:18 UTC
SueWallSt notified investors of a pending investigation into Xenon Pharmaceuticals following the company's disclosure of an enrollment pause in its Phase 3 depression trials for azetukalner, which sent XENE shares down as much as 27.6%.
Source:Sep 22, 2026, 11:47 UTC
Wolf Popper LLP announced an investigation into potential claims on behalf of purchasers of Xenon Pharmaceuticals Inc. common stock.
Source:Sep 17, 2026, 20:38 UTC
Xenon Pharmaceuticals temporarily paused enrollment of new patients in its clinical studies of an experimental drug for major depression and bipolar disorder following reports of mental and nervous system-related side effects.
Sep 17, 2026, 20:01 UTC
Xenon Pharmaceuticals submitted a New Drug Application to the U.S. Food and Drug Administration for azetukalner for the treatment of focal seizures.
Aug 25, 2026, 07:55 UTC
BlackRock Inc. acquired a new minority stake in Xenon Pharmaceuticals Inc., buying 7,522,482 shares valued at approximately $454.06 million, representing about 7.78% ownership, as disclosed in a 13F filing.
Source:Aug 7, 2026, 05:24 UTC
Xenon Pharmaceuticals Inc. held its Q2 2026 earnings call on August 6, 2026.
Source: